Details of the Drug Reposition

General Information of This Drug (ID: DMC5TV6)

Drug Name
TPI-287   DMC5TV6
Synonyms
849213-15-6; (1S,2S,4S,7S,7aR,7a1S,10aS,11aR,13aS,13bR)-1-(benzoyloxy)-4-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-5-methylhexanoyl)oxy)-2-hydroxy-5,7a1,14,14-tetramethyl-9-vinyl-2,3,4,7,7a,7a1,10a,11,11a,13,13a,13b-dodecahydro-1H-8,10,12-trioxa-2,6-methanocyclobuta[b]cyclodeca[de]naphthalene-7,13a-diyl diacetate; TPI 287; SCHEMBL10000720; DTXSID50233967; Q27273546
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Glioblastoma multiforme DISK8246 2A00.0 Phase 2 [1]
Breast cancer DIS7DPX1 2C60-2C65 Phase 2 [2]
------------------------------------------------------------------------------------
2 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Progressive supranuclear palsy DISO5KRQ 8A00.10 Phase 1 [3]
Alzheimer disease DISF8S70 8A20 Phase 1 [4]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02047214) Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT01332630) TPI 287 in Breast Cancer Metastatic to the Brain. U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT02133846) Safety Study of TPI-287 to Treat CBS and PSP (TPI-287-4RT). U.S. National Institutes of Health.
4 ClinicalTrials.gov (NCT01966666) A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease. U.S. National Institutes of Health.